A Phase 1/2 Dose-Escalation & Dose-Expansion Study of the Safety & Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / Acute Lymphoblastic Lymphoma (LBL)

Time: 2:45 pm
day: Day 2 - Track B - Afternoon


  • Introducing WU-CART-007 an allogeneic, fratricide resistant CAR-T cells for the treatment of CD7 hematological malignancies
  • Discuss clinical development plans and trial update